Christine Leaute Labreze, a Dermatologist from Bordeaux University Hospital, France, who shared her first observations around the efficacy of propranolol in certain types of infantile hemangiomas, in a 2008 letter featured in the New England Journal of Medicine (NEJM)[sup.
This placebo controlled trial has been designed to determine the dose, the duration of treatment and the efficacy of propranolol in infantile hemangiomas.
Current management of infantile hemangiomas and their common associated conditions.
Propranolol may become first-line treatment in obstructive subglottic infantile hemangiomas
Drolet BA, Chamlin SL, Garzon MC, et al: A prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin.
Huang SA, Tu HM, Harney JW, et al: Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas.
This would explain the well-documented increased frequency of infantile hemangiomas following chorionic villus sampling to detect fetal anomalies.
As for the postnatal rapid growth of infantile hemangiomas, the most attractive hypothesis is that this results because upon separation from the placenta, the baby is suddenly freed of the influence of soluble Flt-1 and other as yet unknown placentally released inhibitors of inappropriate angiogenesis.
She proceeded to highlight a pilot study in France that showed rapid improvement with the use of propranolol in nine infants with severe infantile hemangiomas
A review of the Infantile Hemangiomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of the Infantile Hemangiomas pipeline on the basis of route of administration and molecule type.
Prior research suggests that abnormal placentas increase the likelihood of infantile hemangiomas
through shearing and embolization of placental tissue.